[go: up one dir, main page]

BRPI0410091A - vacina para vìrus influenza eqüina, e, método para induzir uma resposta imune contra vìrus influenza eqüina - Google Patents

vacina para vìrus influenza eqüina, e, método para induzir uma resposta imune contra vìrus influenza eqüina

Info

Publication number
BRPI0410091A
BRPI0410091A BRPI0410091-3A BRPI0410091A BRPI0410091A BR PI0410091 A BRPI0410091 A BR PI0410091A BR PI0410091 A BRPI0410091 A BR PI0410091A BR PI0410091 A BRPI0410091 A BR PI0410091A
Authority
BR
Brazil
Prior art keywords
vaccine
influenza virus
virus
equine influenza
dna
Prior art date
Application number
BRPI0410091-3A
Other languages
English (en)
Inventor
Alexander Lai
Original Assignee
Univ Oklahoma State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oklahoma State filed Critical Univ Oklahoma State
Publication of BRPI0410091A publication Critical patent/BRPI0410091A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

"VACINA PARA VìRUS INFLUENZA EQüINA, E, MéTODO PARA INDUZIR UMA RESPOSTA IMUNE CONTRA VìRUS INFLUENZA EQüINA". A invenção refere-se a uma vacina de DNA que expressa o gene de hemaglutinina (HA1) do virus influenza eqüina-2. Manipulando-se um códon de interrupção no HA1, assegura-se a expressão de HA1. A encapsulação da vacina de DNA em lipossoma e a inoculação intranasal, é suficiente para elicitar imunidade protetora a uma dosagem significativamente menor se comparada com uma vacina de DNA que expressa o gene HA de comprimento total. Dosagem menor reduz o risco de indução de anticorpos anti-DNA. Inoculação intranasal diretamente nas células epiteliais respiratórias reduz o risco de integração de DNA. A vacina de acordo com a invenção é vantajosa relativamente a vacinas correntes inativadas ou vivas atenuadas, porque a atualização da vacina requer apenas a substituição da seqüência codificadora com o novo vírus.
BRPI0410091-3A 2003-05-15 2004-04-16 vacina para vìrus influenza eqüina, e, método para induzir uma resposta imune contra vìrus influenza eqüina BRPI0410091A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47084303P 2003-05-15 2003-05-15
PCT/US2004/011998 WO2005014778A2 (en) 2003-05-15 2004-04-16 Dna vaccine expressing ha1 of equine-2 influenza virus

Publications (1)

Publication Number Publication Date
BRPI0410091A true BRPI0410091A (pt) 2006-06-06

Family

ID=34135039

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410091-3A BRPI0410091A (pt) 2003-05-15 2004-04-16 vacina para vìrus influenza eqüina, e, método para induzir uma resposta imune contra vìrus influenza eqüina

Country Status (12)

Country Link
US (1) US7244435B2 (pt)
EP (1) EP1623015A4 (pt)
JP (1) JP2007525456A (pt)
KR (1) KR20060035602A (pt)
CN (1) CN1925870A (pt)
AU (1) AU2004263816A1 (pt)
BR (1) BRPI0410091A (pt)
CA (1) CA2523676A1 (pt)
MX (1) MXPA05012199A (pt)
NZ (1) NZ543196A (pt)
WO (1) WO2005014778A2 (pt)
ZA (1) ZA200509187B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
EP1687017B1 (en) 2003-10-24 2013-03-06 Gencia Corporation Methods and compositions for delivering polynucleotides
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
RU2449014C2 (ru) * 2005-04-21 2012-04-27 Юниверсити Оф Флорида Рисерч Фаундейшн, Инк. Штамм вируса гриппа а собак (варианты), иммуногенный полипептид, полинуклеотид, кодирующий его, вектор экспрессии полипептида, иммуногенная композиция, содержащая полипептид, и способ индукции иммунного ответа у животного
KR101484305B1 (ko) * 2006-03-10 2015-01-19 위스콘신 얼럼나이 리서어치 화운데이션 Ｈ3 말 인플루엔자 ａ 바이러스
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
CN101502649B (zh) * 2008-06-23 2011-11-30 深圳职业技术学院 一种脂质体流感疫苗
MX2012000372A (es) 2009-07-06 2012-02-28 Variation Biotechnologies Inc Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CN101886084B (zh) * 2010-03-17 2012-05-30 王世霞 一种密码子优化的h3ha/xj3-07基因及其核酸疫苗
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
CA2862871C (en) 2011-01-13 2020-09-22 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
MX359103B (es) 2011-01-13 2018-09-14 Variation Biotechnologies Inc Composiciones y sus usos en el tratamiento de infecciones virales.
WO2013072768A2 (en) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
EP4008354A1 (en) 2012-01-27 2022-06-08 Variation Biotechnologies Inc. Methods and compositions for therapeutic agents
KR101588334B1 (ko) * 2013-07-02 2016-01-27 대한민국 강독화된 인플루엔자 바이러스 변이주
KR101493613B1 (ko) * 2013-10-25 2015-02-13 위스콘신 얼럼나이 리서어치 화운데이션 Ｈ3 말 인플루엔자 ａ 바이러스

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683137A (en) 1982-04-16 1987-07-28 Cornell Research Foundation, Inc. Temperature sensitive reassortant viruses and a vaccine against equine influenza
GB8300467D0 (en) 1983-01-08 1983-02-09 Wellcome Found Equine influenza
US4920213A (en) 1985-06-20 1990-04-24 Biotechnology Research Partners, Ltd. Method and compositions useful in preventing equine influenza
US4631191A (en) 1985-06-20 1986-12-23 Biotechnology Research Partners, Ltd. Methods and compositions useful in preventing equine influenza
US4619827A (en) 1985-10-07 1986-10-28 Neogen Corporation Method for administering equine vaccines and compositions therefor
US4689224A (en) 1985-10-07 1987-08-25 Neogen Corporation Method for administering vaccines containing equine leukokines and compositions therefor
ZA973642B (en) 1996-04-26 1997-11-25 Merck & Co Inc DNA vaccine formulations.
WO1999004009A1 (en) * 1997-07-14 1999-01-28 Wisconsin Alumni Research Foundation Method of dna vaccination using dna encoding antigen and encoding il6
US6482414B1 (en) 1998-08-13 2002-11-19 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US6177082B1 (en) 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US6398774B1 (en) 1999-09-29 2002-06-04 Heska Corporation Intranasal delivery system
US20030008000A1 (en) 2001-03-08 2003-01-09 Wong Jonathan P. DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus

Also Published As

Publication number Publication date
AU2004263816A1 (en) 2005-02-17
EP1623015A2 (en) 2006-02-08
CA2523676A1 (en) 2005-02-17
JP2007525456A (ja) 2007-09-06
CN1925870A (zh) 2007-03-07
WO2005014778A3 (en) 2006-10-05
KR20060035602A (ko) 2006-04-26
US20050032732A1 (en) 2005-02-10
EP1623015A4 (en) 2007-10-10
ZA200509187B (en) 2007-12-27
WO2005014778A2 (en) 2005-02-17
US7244435B2 (en) 2007-07-17
MXPA05012199A (es) 2006-02-10
NZ543196A (en) 2008-04-30

Similar Documents

Publication Publication Date Title
BRPI0410091A (pt) vacina para vìrus influenza eqüina, e, método para induzir uma resposta imune contra vìrus influenza eqüina
Couch Seasonal inactivated influenza virus vaccines
Liu et al. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections
Lu et al. Effect of mucosal and systemic immunization with virus‐like particles of severe acute respiratory syndrome coronavirus in mice
Pica et al. NS1-truncated live attenuated virus vaccine provides robust protection to aged mice from viral challenge
Liu et al. Recombinant virus-like particles elicit protective immunity against avian influenza A (H7N9) virus infection in ferrets
Kamlangdee et al. Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene
Wang et al. Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand
EP1270016A4 (en) VACCINE AGAINST AIDS VIRUS CONTAINING A VECTOR OF SENDAI VIRUS
Major et al. Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge
DK1216053T3 (da) Influenzavaccine
Cox et al. Development of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine
Zheng et al. Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses
Wraith et al. Induction of influenza A virus cross-reactive cytotoxic T cells by a nucleoprotein/haemagglutinin preparation
ATE352557T1 (de) Rekombinantes nukleoprotein von newcastle- krankheitsvirus als markierungsimpfstoff
Lahiri et al. Intragastric delivery of recombinant Lactococcus lactis displaying ectodomain of influenza matrix protein 2 (M2e) and neuraminidase (NA) induced focused mucosal and systemic immune responses in chickens
Hatta et al. An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus
BRPI0512421B8 (pt) Recombinantes de avipox expressando genes do vírus da doença febre aftosa
Lei et al. Protective immunity against influenza H5N1 virus challenge in chickens by oral administration of recombinant Lactococcus lactis expressing neuraminidase
Safdar et al. Baculovirus-expressed influenza vaccine: a novel technology for safe and expeditious vaccine production for human use
JP2018525028A5 (pt)
Hasegawa et al. Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses
Lei et al. Cross-protective immunity of the haemagglutinin stalk domain presented on the surface of Lactococcus lactis against divergent influenza viruses in mice
EP1523333A4 (en) USE OF VACCINIA VIRUS WITH DELETION OF E3L GENE AS VACCINE VECTOR
EP1155119A4 (en) VIRUS VACCINE CHARACTERIZED BY BHV-1 GENE DELETION

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.